Opioid harm reduction strategies: focus on expanded access to intranasal naloxone.
Wermeling
Daniel P
DP
D000281:Administration, Intranasal; D040261:Harm Reduction; D006801:Humans; D009270:Naloxone / Q000008:administration & dosage*; D009292:Narcotic Antagonists / Q000008:administration & dosage*
D009292:Narcotic Antagonists; D009270:Naloxone